1 / 15

MSF Access Campaign

MSF Access Campaign. Started in 1999 Rooted in field experience Three Pillars: Overcoming Barriers Research and Development for Drugs for Neglected Diseases Effects of Globalisation (TRIPS, etc). Access to Essential Medicines. 75% of the world’s population live in developing countries

quanda
Download Presentation

MSF Access Campaign

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. MSF Access Campaign • Started in 1999 • Rooted in field experience • Three Pillars: • Overcoming Barriers • Research and Development for Drugs for Neglected Diseases • Effects of Globalisation (TRIPS, etc)

  2. Access to Essential Medicines 75% of the world’s population live in developing countries They account for 8% of the pharmaceutical sales 1/3 world’s population does not have access to essential medicines (> 50% in most impoverished areas of Africa and Asia)

  3. Projected WorldPharmaceutical Market 2002(around 400 billions USD)

  4. World Drugs Market Billions US$ Source: IMS Health, PNUD

  5. Factors Affecting Access to Essential Medicines R&D Production Approval Quality Distribution Drug information, rationale use Diagnosis/prescription/monitoring Price Compliance Pharmacovigilance

  6. WHO/CDS/CSR Evolution of Sleeping Sickness Throughout the XXth Century

  7. 1995-2000 Suramine et Nifurtimox Bayer ends the production. Melarsoprol (Aventis) Production in danger Pentamidine (RPR-Aventis) Announces a progressive end to the donation programme Eflornithine (HMR-Aventis) ends the production (exploitation is offered to WHO) 2001 Bayer announces production and donation re-commencement Aventis annonce maintenance of the production and donation programme for 5 years + support to sleeping sickess programmes . Drugs for sleeping sickness: Preliminary Results

  8. Unaffordable Life-saving drugs • Anti-retrovirals • Some treatments for opportunistic diseases • New antibiotics or anti-malaria drugs • New vaccines • Etc.

  9. Objective:Equitable Drug Prices • The policy of assuring dramatically reduced drug prices so that they are truly affordable to the people who need them • A policy that is • sustainable (not based on charity or donations) • Strengthens developing countries’ autonomy • Attracts donor funding • Not limited to HIV/AIDS medication only

  10. Generic CompetitionSample AIDS triple-combination: lowest world prices (stavudine (d4T) + lamivudine (3TC) + nevirapine)

  11. Lack of Research and Development for Neglected Diseases Defining the problems and searching for solutions

  12. Less than 10% is devoted to 90% of the world’s health problems Global investment in R&D • Estimated that between $70 - 90 billion per year spent on health R&D • 50% public funding (of which 80% is G8) • 50% private funding (for profit and non-profit)

  13. Lack of R&D for Neglected Diseases1975 – 1999Among 1393 new chemical entities, 435 (31.2%) therapeutic innovations Therapeutic Innovations for Tropical Diseases 1% Therapeutic Innovations for Other Diseases 30% New chemical entities 69%

  14. Who can play a role in defining solutions • NGO's commitment • The role of the pharmaceutical industry • Public support, • political will and funding

More Related